AORT vs. IRTC, PRCT, NVST, TMDX, SLNO, LIVN, ENOV, NVCR, WRBY, and LMAT
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Envista (NVST), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), Warby Parker (WRBY), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.
Artivion vs.
Artivion (NYSE:AORT) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.
Artivion has a net margin of -0.22% compared to iRhythm Technologies' net margin of -19.14%. Artivion's return on equity of 5.15% beat iRhythm Technologies' return on equity.
86.4% of Artivion shares are held by institutional investors. 8.1% of Artivion shares are held by insiders. Comparatively, 0.7% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Artivion has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
Artivion has higher earnings, but lower revenue than iRhythm Technologies. Artivion is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, iRhythm Technologies had 2 more articles in the media than Artivion. MarketBeat recorded 4 mentions for iRhythm Technologies and 2 mentions for Artivion. iRhythm Technologies' average media sentiment score of 1.42 beat Artivion's score of 0.84 indicating that iRhythm Technologies is being referred to more favorably in the news media.
iRhythm Technologies received 382 more outperform votes than Artivion when rated by MarketBeat users. However, 81.82% of users gave Artivion an outperform vote while only 66.07% of users gave iRhythm Technologies an outperform vote.
Artivion presently has a consensus target price of $31.40, indicating a potential upside of 27.38%. iRhythm Technologies has a consensus target price of $119.73, indicating a potential upside of 12.31%. Given Artivion's stronger consensus rating and higher possible upside, equities analysts clearly believe Artivion is more favorable than iRhythm Technologies.
Summary
Artivion beats iRhythm Technologies on 11 of the 18 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artivion Competitors List
Related Companies and Tools
This page (NYSE:AORT) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy AORT Stock Free AORT Stock Alerts